Medigen Biotechnology Corp - Company Profile
Powered by
All the data and insights you need on Medigen Biotechnology Corp in one report.
- Save hours of research time and resources with
our up-to-date Medigen Biotechnology Corp Strategy Report
- Understand Medigen Biotechnology Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Medigen Biotechnology Corp (MBC) is a pharmaceutical company that carries out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. It focuses on developing new therapeutics, principally in the area of cancer and liver diseases. The company’s product portfolio includes monoclonal antibodies; vaccines; molecular diagnostics and generic drugs. MBC also provides original equipment manufacturing (OEM) and original design manufacturing (ODM) manufacturing services in various dosage forms including orals, externals, ophthalmic and hormones; nutrition supplements; cosmeceutical products. The company’s subsidiaries include Medigen Vaccine Biologics; TBG Biotechnology Corp; and Winston Medical Supply Co Ltd. MBC is headquartered in Taipei city, Taiwan.
Medigen Biotechnology Corp premium industry data and analytics
Products and Services
Products | Services |
---|---|
Molecular Diagnostics | Drug Development Services |
Generic Drugs | Original Design Manufacturing |
Medical Aesthetic Products | Original Equipment Manufacturing |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | Medigen Biotechnology Corp | PhytoHealth Corp | NeoCore Technology Co Ltd | Lumosa Therapeutics Co Ltd | Development Center for Biotechnology |
---|---|---|---|---|---|
Headquarters | Taiwan | Taiwan | Taiwan | Taiwan | Taiwan |
City | Taipei | Taipei | Tainan | Taipei | Taipei |
State/Province | - | - | - | - | Taipei |
No. of Employees | 67 | 84 | 37 | 47 | 400 |
Entity Type | Public | Public | Public | Public | Institution |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Stanley Chang, Ph.D., M.D. | Chairman; Chief Executive Officer | Executive Board | - | - |
Alarng Chang | General Manager | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer